Characterization of opioid binding sites in murine neuroblastoma

Ian S. Zagon, Steven Goodman, Patricia J. McLaughlin

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The binding of [3H][d-Ala2,MePhe4,Gly-ol5]enkephalin ([3H]DAGO), [3H]d-Ala2,d-Leu5]enkephalin [3H]DADLE) and (±)-[3H]ethylketocyclazocine ([3H]EKC) to neurotumor tissues derived from S20Y neuroblastoma cells transplanted into A/Jax mice was examined. Specific and saturable binding to [3H]DADLE and [3H]EKC was detected, and the data fit a single homogenous binding site for each ligand. Scatchard analysis for [3H]DADLE and [3H]EKC yielded Kd values of 0.65 and 0.45 nM, respectively, and Bmax values of 9.2 and 116 fmol/mg protein. Binding was dependent on time, temperature, and pH, and was sensitive to Na+ and guanine nucleotides. Pretreatment of the tumor homogenates with trypsin markedly reduced binding to both ligands, suggesting that the binding sites were proteinaceous in character. Displacement experiments indicated that delta (δ) receptor related compounds (e.g. DPDPE, ICI 174,864) avidly displaced [3H]DADLE, whereas kappa (κ) related compounds (e.g. U50, 488, dynorphin) markedly competed with [3H]EKC. Mu (μ) receptor drugs (e.g. DAGO, β-FNA, morphine) were not potent in displacing either [3H]DADLE or [3H]EKC. These results are the first to characterize opioid binding sites in tumor tissue. The function of these sites is nuclear, but previous evidence as to the growth regulatory properties of endogenous opioid systems may suggest that either one, or both, binding sites may be involved in carcinogenic events.

Original languageEnglish (US)
Pages (from-to)80-88
Number of pages9
JournalBrain Research
Volume449
Issue number1-2
DOIs
StatePublished - May 24 1988
Externally publishedYes

Fingerprint

Leucine-2-Alanine Enkephalin
Neuroblastoma
Opioid Analgesics
Binding Sites
Enkephalins
Ethylketocyclazocine
D-Penicillamine (2,5)-Enkephalin
Ala(2)-MePhe(4)-Gly(5)-enkephalin
Ligands
Dynorphins
delta Opioid Receptor
Guanine Nucleotides
mu Opioid Receptor
Trypsin
Morphine
Neoplasms
Temperature
Growth
Pharmaceutical Preparations
Proteins

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this

Characterization of opioid binding sites in murine neuroblastoma. / Zagon, Ian S.; Goodman, Steven; McLaughlin, Patricia J.

In: Brain Research, Vol. 449, No. 1-2, 24.05.1988, p. 80-88.

Research output: Contribution to journalArticle

Zagon, Ian S. ; Goodman, Steven ; McLaughlin, Patricia J. / Characterization of opioid binding sites in murine neuroblastoma. In: Brain Research. 1988 ; Vol. 449, No. 1-2. pp. 80-88.
@article{df5f9963935149f591f61f9b459fc6d0,
title = "Characterization of opioid binding sites in murine neuroblastoma",
abstract = "The binding of [3H][d-Ala2,MePhe4,Gly-ol5]enkephalin ([3H]DAGO), [3H]d-Ala2,d-Leu5]enkephalin [3H]DADLE) and (±)-[3H]ethylketocyclazocine ([3H]EKC) to neurotumor tissues derived from S20Y neuroblastoma cells transplanted into A/Jax mice was examined. Specific and saturable binding to [3H]DADLE and [3H]EKC was detected, and the data fit a single homogenous binding site for each ligand. Scatchard analysis for [3H]DADLE and [3H]EKC yielded Kd values of 0.65 and 0.45 nM, respectively, and Bmax values of 9.2 and 116 fmol/mg protein. Binding was dependent on time, temperature, and pH, and was sensitive to Na+ and guanine nucleotides. Pretreatment of the tumor homogenates with trypsin markedly reduced binding to both ligands, suggesting that the binding sites were proteinaceous in character. Displacement experiments indicated that delta (δ) receptor related compounds (e.g. DPDPE, ICI 174,864) avidly displaced [3H]DADLE, whereas kappa (κ) related compounds (e.g. U50, 488, dynorphin) markedly competed with [3H]EKC. Mu (μ) receptor drugs (e.g. DAGO, β-FNA, morphine) were not potent in displacing either [3H]DADLE or [3H]EKC. These results are the first to characterize opioid binding sites in tumor tissue. The function of these sites is nuclear, but previous evidence as to the growth regulatory properties of endogenous opioid systems may suggest that either one, or both, binding sites may be involved in carcinogenic events.",
author = "Zagon, {Ian S.} and Steven Goodman and McLaughlin, {Patricia J.}",
year = "1988",
month = "5",
day = "24",
doi = "10.1016/0006-8993(88)91026-8",
language = "English (US)",
volume = "449",
pages = "80--88",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Characterization of opioid binding sites in murine neuroblastoma

AU - Zagon, Ian S.

AU - Goodman, Steven

AU - McLaughlin, Patricia J.

PY - 1988/5/24

Y1 - 1988/5/24

N2 - The binding of [3H][d-Ala2,MePhe4,Gly-ol5]enkephalin ([3H]DAGO), [3H]d-Ala2,d-Leu5]enkephalin [3H]DADLE) and (±)-[3H]ethylketocyclazocine ([3H]EKC) to neurotumor tissues derived from S20Y neuroblastoma cells transplanted into A/Jax mice was examined. Specific and saturable binding to [3H]DADLE and [3H]EKC was detected, and the data fit a single homogenous binding site for each ligand. Scatchard analysis for [3H]DADLE and [3H]EKC yielded Kd values of 0.65 and 0.45 nM, respectively, and Bmax values of 9.2 and 116 fmol/mg protein. Binding was dependent on time, temperature, and pH, and was sensitive to Na+ and guanine nucleotides. Pretreatment of the tumor homogenates with trypsin markedly reduced binding to both ligands, suggesting that the binding sites were proteinaceous in character. Displacement experiments indicated that delta (δ) receptor related compounds (e.g. DPDPE, ICI 174,864) avidly displaced [3H]DADLE, whereas kappa (κ) related compounds (e.g. U50, 488, dynorphin) markedly competed with [3H]EKC. Mu (μ) receptor drugs (e.g. DAGO, β-FNA, morphine) were not potent in displacing either [3H]DADLE or [3H]EKC. These results are the first to characterize opioid binding sites in tumor tissue. The function of these sites is nuclear, but previous evidence as to the growth regulatory properties of endogenous opioid systems may suggest that either one, or both, binding sites may be involved in carcinogenic events.

AB - The binding of [3H][d-Ala2,MePhe4,Gly-ol5]enkephalin ([3H]DAGO), [3H]d-Ala2,d-Leu5]enkephalin [3H]DADLE) and (±)-[3H]ethylketocyclazocine ([3H]EKC) to neurotumor tissues derived from S20Y neuroblastoma cells transplanted into A/Jax mice was examined. Specific and saturable binding to [3H]DADLE and [3H]EKC was detected, and the data fit a single homogenous binding site for each ligand. Scatchard analysis for [3H]DADLE and [3H]EKC yielded Kd values of 0.65 and 0.45 nM, respectively, and Bmax values of 9.2 and 116 fmol/mg protein. Binding was dependent on time, temperature, and pH, and was sensitive to Na+ and guanine nucleotides. Pretreatment of the tumor homogenates with trypsin markedly reduced binding to both ligands, suggesting that the binding sites were proteinaceous in character. Displacement experiments indicated that delta (δ) receptor related compounds (e.g. DPDPE, ICI 174,864) avidly displaced [3H]DADLE, whereas kappa (κ) related compounds (e.g. U50, 488, dynorphin) markedly competed with [3H]EKC. Mu (μ) receptor drugs (e.g. DAGO, β-FNA, morphine) were not potent in displacing either [3H]DADLE or [3H]EKC. These results are the first to characterize opioid binding sites in tumor tissue. The function of these sites is nuclear, but previous evidence as to the growth regulatory properties of endogenous opioid systems may suggest that either one, or both, binding sites may be involved in carcinogenic events.

UR - http://www.scopus.com/inward/record.url?scp=0023913622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023913622&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(88)91026-8

DO - 10.1016/0006-8993(88)91026-8

M3 - Article

VL - 449

SP - 80

EP - 88

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -